STOCK TITAN

InMed Pharmaceuticals: Fairmount holds 10.6M shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
3

Rhea-AI Filing Summary

InMed Pharmaceuticals Inc. (INM) reports that Fairmount Healthcare Fund II L.P. indirectly held 10,555,507 common shares as of November 6, 2026, following a merger exchange effective that day. The fund also held 4,013 shares of Series A non-voting convertible preferred stock representing 4,013,000 underlying common shares, plus pre-funded warrants for 1,468,222 common shares exercisable at $0.0001 each.

Fairmount Funds Management LLC, Peter Evan Harwin and Tomas Kiselak are also identified as ten-percent owners. They disclaim beneficial ownership except to the extent of their pecuniary interest. The preferred stock and warrants carry 19.99% beneficial-ownership limits; the preferred-stock limit automatically becomes 9.99% when ownership is 9.00% or less.

Insider Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Kiselak Tomas, Harwin Peter Evan
Role 10% Owner | 10% Owner | 10% Owner | 10% Owner
Type Security Shares Price Value
Holding Series A Non-Voting Preferred Stock F4, F5, F1, F6, F3 -- -- --
Holding Pre-funded Warrant F7, F8, F1, F9, F3 -- -- --
Holding Common Stock F1, F2, F3 -- -- --
Holdings: Series A Non-Voting Preferred Stock — 4,013,000 shares (Indirect, By Fairmount Healthcare Fund II L.P.); Pre-funded Warrant — 1,468,222 warrants (Indirect, By Fairmount Healthcare Fund II L.P.); Common Stock — 10,555,507 shares (Indirect, By Fairmount Healthcare Fund II L.P.)
Footnotes (9)
  1. F1. Effective as of November 6, 2026 (the "Effective Time"), (i) Indigo Merger Sub Corp., a wholly owned subsidiary of Mentari Therapeutics, Inc. (formerly known as InMed Pharmaceuticals Inc.), a Nevada corporation (the "Issuer"), merged with and into Mentari Therapeutics, Inc., a Delaware corporation ("Pre-Merger Mentari"), with Pre-Merger Mentari continuing as a wholly owned subsidiary of the Issuer and the surviving corporation of the merger (the "First Merger"), and (ii) immediately thereafter, Pre-Merger Mentari merged with and into Indigo Merger Sub II, LLC, a second wholly owned subsidiary of the Issuer ("Second Merger Sub"), with Second Merger Sub being the surviving entity of the merger under the name Mentari Therapeutics Operating Company LLC (the "Second Merger" and, together with the First Merger, the "Merger").
  2. F2. Represents the number of shares of the Issuer's common stock received by the Reporting Person in the Merger in exchange for the shares of Pre-Merger Mentari's common stock and Series A Preferred Stock held by the Reporting Person prior to the Merger. Each share of Pre-Merger Mentari's common stock and Series A Preferred Stock held at the Effective Time was exchanged for 0.20065 shares of the Issuer's common stock.
  3. F3. Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. Peter Harwin and Tomas Kiselak are the managers of Fairmount. Fairmount, Mr. Harwin and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
  4. F4. Series A Non-Voting Convertible Preferred Stock of the Issuer, par value $0.0001 per share (the "Issuer Preferred Stock"), has no expiration date and is convertible at any time and from time to time at the option of the holder thereof into a number of shares of the Issuer's common stock equal to the Conversion Ratio, initially 1,000 shares of common stock for each share of Issuer Preferred Stock, subject to adjustment. A holder may not convert Issuer Preferred Stock to the extent that, after giving effect to the conversion, the holder, together with its affiliates and any other persons whose beneficial ownership would be aggregated with the holder's for purposes of Section 13(d) or Section 16 of the Securities Exchange Act of 1934, including any group of which the holder is a member, would beneficially own shares of common stock in excess of the applicable beneficial ownership limitation, which the Reporting Person has designated as 19.99% of the shares of common stock outstanding.
  5. F5. (Continued from footnote 4) A holder may reset that limitation to a lower percentage effective immediately, or to a higher percentage not exceeding 19.99% effective on the 61st day after written notice to the Issuer, and the limitation is automatically set at 9.99% at any time the holder's beneficial ownership is 9.00% or less of the outstanding common stock.
  6. F6. Represents the number of shares of the Issuer's common stock underlying 4,013 shares of Issuer Preferred Stock received by the Reporting Person in the Merger in exchange for the shares of Pre-Merger Mentari's Series Seed Preferred Stock ("Mentari Series Seed Preferred Stock") held by the Reporting Person prior to the Merger. Each share of Mentari Series Seed Preferred Stock held at the Effective Time was exchanged for 0.00020065 shares of Issuer Preferred Stock.
  7. F7. The pre-funded warrants to purchase shares of the Issuer's common stock (the "Issuer Pre-Funded Warrants") have no expiration date and are exercisable at any time and from time to time on or after the date of issuance. A holder may not exercise the Issuer Pre-Funded Warrants to the extent that, immediately prior to or following the exercise, the holder, together with its affiliates and any other persons whose beneficial ownership would be aggregated with the holder's for purposes of Section 13(d) of the Securities Exchange Act of 1934, would beneficially own shares of common stock in excess of the maximum percentage applicable to such holder, which the Reporting Person has elected to be 19.99% of the shares of common stock issued and outstanding following the exercise.
  8. F8. (Continued from footnote 7) A holder may increase or decrease that maximum percentage by written notice to the Issuer, provided that it may not exceed 19.99% and that any increase is not effective until the 61st day after the notice is delivered to the Issuer.
  9. F9. Represents the number of Issuer Pre-Funded Warrants received by the Reporting Person in the Merger in exchange for pre-funded warrants to purchase shares of Pre-Merger Mentari's common stock (the "Mentari Pre-Funded Warrants") held by the Reporting Person prior to the Merger. Each Mentari Pre-Funded Warrant held at the Effective Time was exchanged for 0.20065 Issuer Pre-Funded Warrants.
Common shares held 10,555,507 shares Indirectly held by Fairmount Healthcare Fund II L.P. as of November 6, 2026
Series A preferred stock held 4,013 shares Held by Fairmount Healthcare Fund II L.P.
Common shares underlying preferred stock 4,013,000 shares Underlying the fund's Series A preferred stock
Common shares underlying pre-funded warrants 1,468,222 shares Warrants held by Fairmount Healthcare Fund II L.P.
Pre-funded warrant exercise price $0.0001 per share Exercise price for the issuer's pre-funded warrants
Preferred-stock beneficial-ownership limit 19.99% Limit on conversion based on beneficial ownership
Automatic preferred-stock limit 9.99% when ownership is 9.00% or less The preferred-stock limit is automatically set to 9.99% under this condition
beneficial ownership limitation regulatory
"the applicable beneficial ownership limitation"
A beneficial ownership limitation is a rule that caps the percentage of a company’s shares an investor can be treated as owning or controlling for voting, regulatory or tax purposes. It matters to investors because it can restrict how many shares a person or group can buy or vote, affect takeover chances, and influence share liquidity and value — like a speed limit that prevents any single driver from taking over the whole road.
Conversion Ratio technical
"equal to the Conversion Ratio"
The conversion ratio is the number of common shares an investor receives when a convertible security (like a bond or preferred share) or an exchangeable instrument is turned into ordinary stock. It matters because it tells investors how much ownership or dilution will occur — similar to knowing how many slices you get when you trade in a coupon — and directly affects the value you get from the convertible and the company’s future share count.
pre-funded warrants financial
"pre-funded warrants to purchase shares of the Issuer's common stock"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
pecuniary interest financial
"except to the extent of their pecuniary interest therein"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did Fairmount Healthcare Fund II hold in INM?

Fairmount Healthcare Fund II L.P. held 10,555,507 common shares, 4,013 shares of Series A preferred stock representing 4,013,000 underlying common shares, and pre-funded warrants for 1,468,222 common shares as of November 6, 2026.

What ownership limits apply to INM preferred stock and warrants?

The preferred stock cannot be converted if conversion would put the holder and aggregated persons above 19.99% ownership. The limit can be lowered immediately or raised up to 19.99% effective on the 61st day after written notice; it automatically becomes 9.99% when ownership is 9.00% or less. The warrants also have a 19.99% limit, and an increase by written notice takes effect on the 61st day.

What exchange ratio applied to pre-merger Mentari shares in the INM merger?

Each share of Pre-Merger Mentari common stock and Series A Preferred Stock held at the effective time was exchanged for 0.20065 shares of the issuer's common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Fairmount Funds Management LLC

(Last)(First)(Middle)
200 BARR HARBOR DRIVE, SUITE 400

(Street)
WEST CONSHOHOCKEN PENNSYLVANIA 19428

(City)(State)(Zip)

UNITED STATES

(Country)
2. Date of Event Requiring Statement (Month/Day/Year)
11/06/2026
3. Issuer Name and Ticker or Trading Symbol
InMed Pharmaceuticals Inc. [ MTRI ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
DirectorX10% Owner
Officer (give title below)Other (specify below)
6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
XForm filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock10,555,507(1)(2)IBy Fairmount Healthcare Fund II L.P.(3)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Series A Non-Voting Preferred Stock (4)(5) (4)(5)Common Stock4,013,000(1)(4)(5)(6)(4)(5)IBy Fairmount Healthcare Fund II L.P.(3)
Pre-funded Warrant (7)(8) (7)(8)Common Stock1,468,222(1)(9)$0.0001IBy Fairmount Healthcare Fund II L.P.(3)
1. Name and Address of Reporting Person*
Fairmount Funds Management LLC

(Last)(First)(Middle)
200 BARR HARBOR DRIVE, SUITE 400

(Street)
WEST CONSHOHOCKEN PENNSYLVANIA 19428

(City)(State)(Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
Fairmount Healthcare Fund II L.P.

(Last)(First)(Middle)
200 BARR HARBOR DRIVE, SUITE 400

(Street)
WEST CONSHOHOCKEN PENNSYLVANIA 19428

(City)(State)(Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
Kiselak Tomas

(Last)(First)(Middle)
200 BARR HARBOR DRIVE, SUITE 400

(Street)
WEST CONSHOHOCKEN PENNSYLVANIA 19428

(City)(State)(Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
Harwin Peter Evan

(Last)(First)(Middle)
200 BARR HARBOR DRIVE, SUITE 400

(Street)
WEST CONSHOHOCKEN PENNSYLVANIA 19428

(City)(State)(Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
Explanation of Responses:
1. Effective as of November 6, 2026 (the "Effective Time"), (i) Indigo Merger Sub Corp., a wholly owned subsidiary of Mentari Therapeutics, Inc. (formerly known as InMed Pharmaceuticals Inc.), a Nevada corporation (the "Issuer"), merged with and into Mentari Therapeutics, Inc., a Delaware corporation ("Pre-Merger Mentari"), with Pre-Merger Mentari continuing as a wholly owned subsidiary of the Issuer and the surviving corporation of the merger (the "First Merger"), and (ii) immediately thereafter, Pre-Merger Mentari merged with and into Indigo Merger Sub II, LLC, a second wholly owned subsidiary of the Issuer ("Second Merger Sub"), with Second Merger Sub being the surviving entity of the merger under the name Mentari Therapeutics Operating Company LLC (the "Second Merger" and, together with the First Merger, the "Merger").
2. Represents the number of shares of the Issuer's common stock received by the Reporting Person in the Merger in exchange for the shares of Pre-Merger Mentari's common stock and Series A Preferred Stock held by the Reporting Person prior to the Merger. Each share of Pre-Merger Mentari's common stock and Series A Preferred Stock held at the Effective Time was exchanged for 0.20065 shares of the Issuer's common stock.
3. Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. Peter Harwin and Tomas Kiselak are the managers of Fairmount. Fairmount, Mr. Harwin and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
4. Series A Non-Voting Convertible Preferred Stock of the Issuer, par value $0.0001 per share (the "Issuer Preferred Stock"), has no expiration date and is convertible at any time and from time to time at the option of the holder thereof into a number of shares of the Issuer's common stock equal to the Conversion Ratio, initially 1,000 shares of common stock for each share of Issuer Preferred Stock, subject to adjustment. A holder may not convert Issuer Preferred Stock to the extent that, after giving effect to the conversion, the holder, together with its affiliates and any other persons whose beneficial ownership would be aggregated with the holder's for purposes of Section 13(d) or Section 16 of the Securities Exchange Act of 1934, including any group of which the holder is a member, would beneficially own shares of common stock in excess of the applicable beneficial ownership limitation, which the Reporting Person has designated as 19.99% of the shares of common stock outstanding.
5. (Continued from footnote 4) A holder may reset that limitation to a lower percentage effective immediately, or to a higher percentage not exceeding 19.99% effective on the 61st day after written notice to the Issuer, and the limitation is automatically set at 9.99% at any time the holder's beneficial ownership is 9.00% or less of the outstanding common stock.
6. Represents the number of shares of the Issuer's common stock underlying 4,013 shares of Issuer Preferred Stock received by the Reporting Person in the Merger in exchange for the shares of Pre-Merger Mentari's Series Seed Preferred Stock ("Mentari Series Seed Preferred Stock") held by the Reporting Person prior to the Merger. Each share of Mentari Series Seed Preferred Stock held at the Effective Time was exchanged for 0.00020065 shares of Issuer Preferred Stock.
7. The pre-funded warrants to purchase shares of the Issuer's common stock (the "Issuer Pre-Funded Warrants") have no expiration date and are exercisable at any time and from time to time on or after the date of issuance. A holder may not exercise the Issuer Pre-Funded Warrants to the extent that, immediately prior to or following the exercise, the holder, together with its affiliates and any other persons whose beneficial ownership would be aggregated with the holder's for purposes of Section 13(d) of the Securities Exchange Act of 1934, would beneficially own shares of common stock in excess of the maximum percentage applicable to such holder, which the Reporting Person has elected to be 19.99% of the shares of common stock issued and outstanding following the exercise.
8. (Continued from footnote 7) A holder may increase or decrease that maximum percentage by written notice to the Issuer, provided that it may not exceed 19.99% and that any increase is not effective until the 61st day after the notice is delivered to the Issuer.
9. Represents the number of Issuer Pre-Funded Warrants received by the Reporting Person in the Merger in exchange for pre-funded warrants to purchase shares of Pre-Merger Mentari's common stock (the "Mentari Pre-Funded Warrants") held by the Reporting Person prior to the Merger. Each Mentari Pre-Funded Warrant held at the Effective Time was exchanged for 0.20065 Issuer Pre-Funded Warrants.
/s/ Peter Harwin, Managing Member of Fairmount Funds Management LLC11/12/2026
/s/ Peter Harwin, Managing Member of Fairmount Healthcare Fund II L.P.11/12/2026
/s/ Tomas Kiselak11/12/2026
/s/ Peter Harwin11/12/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Keep reading